



Canada's source for  
HIV and hepatitis C  
information

La source canadienne  
de renseignements sur  
le VIH et l'hépatite C

## CATIE-News

CATIE's bite-sized HIV and hepatitis C news bulletins.

### **Smoking cessation: Innovative group therapy-centered support found to double quit rate**

19 October 2012

Surveys have found that tobacco use is common among some HIV-positive people. As much as 40% of some clinic populations have been found to smoke cigarettes. In the time before potent combination anti-HIV therapy (commonly called ART or HAART) became widely available, smoking cessation was not a major concern for HIV-positive people and their health care providers.

In the present era, researchers increasingly expect ART users to have survival rates broadly similar to those of HIV-negative people. However, there are increasing reports of shortened survival among some HIV-positive people due to [complications arising from cancers, co-infections and cardiovascular disease](#). Smoking tobacco elevates the risk for cancers, heart attack and other complications, ultimately worsening quality of life and decreasing lifespan. In one international study of more than 5,000 HIV-positive people, researchers estimated that smoking tobacco was either directly or indirectly responsible for 24% of the deaths that occurred over the long term.

#### **Help for quitting**

Concerned about the harmful impact of smoking and trying to improve ways to help HIV-positive people quit, researchers at the Albert Einstein College of Medicine in the Bronx, New York, have been conducting studies related to this issue. Their latest study was a randomized controlled trial comparing an intensive group therapy-centered approach to standard advice about quitting. All participants were offered nicotine replacement therapy. Participants who received intensive group therapy-based support had nearly double the quit rate after three months.

Furthermore, the researchers found that two factors—loneliness and participants' confidence in their ability to resist the urge to smoke—were significantly associated with their ability to break free from smoking. The results of this and other studies should encourage clinicians to refine their tobacco-cessation programs for HIV-positive people.

#### **Study details**

Participants in the study were randomly assigned to either enter the intensive program, called Positive Smoke Free (PSF), or receive brief standard counselling. Within the PSF program, participants were divided into small groups of six to eight people. Each group was led by two facilitators, one was an HIV-positive peer and the other was a graduate student of a psychology program. Both facilitators had training about tobacco addiction.

#### **Focus on PSF**

PSF is an eight-session intervention based on the *Tobacco Dependence Treatment Handbook*. The PSF program was created by making modifications to the work in the handbook, so that the concerns of HIV-positive people could be incorporated. These concerns, identified in pilot studies, included the following:

- specific risks of smoking for HIV-positive people
- co-existing mental health and emotional issues
- substance use
- social isolation
- stress reduction

Each group had a weekly 90-minute session. Key issues covered in these meetings including the following:

- reviewing the many health risks associated with exposure to tobacco smoke
- dispelling myths about the alleged benefits of smoking
- exploring self-discipline and delaying instant gratification and their impact on improved health
- understanding the importance of adherence
- understanding and enduring temporary discomfort in exchange for long-term health
- assertive training to negotiate HIV care
- dealing with urges to skip medical appointments or doses of HIV medications
- understanding the link between HIV, pain, tobacco use and quitting
- remaining free from tobacco over the long-term

Smoke-free status was confirmed by the evaluation of the exhaled air of participants for carbon monoxide at several points throughout the study.

Of the 184 people who volunteered for the study, 147 made it through the screening process and were randomly assigned to one of the following groups:

- 73 participants – PSF
- 72 participants – so-called standard therapy, consisting of a brochure about quitting, brief advice (less than five minutes) about quitting and free nicotine replacement therapy if they wished

The average profile at the time participants entered the study was as follows:

- gender – 50% women, 49% men, 1% transgendered
- age – 48 years
- CD4+ count – 500 cells
- housing status – 90% had stable housing status
- employment – 89% were unemployed

HIV infection risk factors included the following:

- unprotected heterosexual sex – 58%
- unprotected sex between men – 15%
- injection drug use – 15%
- contaminated blood transfusion – 3%

Commonly used substances in the month prior to enrollment in the study were as follows:

- marijuana – 42%
- cocaine – 29%
- heroin – 8%

Most people had been smokers for more than 30 years, consuming an average of 12 cigarettes daily.

## **Results**

Overall, 21 participants (15%) were able to quit after the three-month program ended, distributed as follows:

- PSF – 19%
- standard therapy – 10%

Although the outcome of this study is highly promising and likely clinically meaningful—nearly twice as many PSF participants quit—the difference in quit rates did not reach statistical significance.

The study team assessed possible reasons that might have influenced people to quit, including the following:

- group facilitators – a comparison of different group leaders did not find any impact on outcomes
- prescribed medicines – although 40% of participants received nicotine replacement therapy or other

prescribed drugs, such as bupropion (Wellbutrin, Zyban) and varenicline (Chantix, Champix), to help ease the path to quitting, prescribed medicines on their own did not apparently affect quit rates in this study

- race/ethnicity – people of Latino ethnicity were more likely to quit
- loneliness – people who were lonelier were less likely to quit

## Improvements to the next clinical trial

The PSF program was clearly advantageous in helping people to quit. Researchers found that quit rates were significantly greater among PSF participants if they attended seven or more counselling sessions **and** also received prescribed therapy to help them quit. Keeping people motivated in any clinical trial is not easy, particularly in trials of smoking cessation. Future trials should consider prescribed medicines for smoking cessation as well as ways to maximize attendance at support group meetings. Additional considerations include the following:

- race/ethnicity – Researchers are not certain why Latino participants were more likely to quit smoking in the present study. They found that Black people were less likely to quit and so more research is needed to understand these issues concerning race and ethnicity.
- loneliness – Past research has found that loneliness is linked to an increased risk for tobacco use. Perhaps this may be related to boredom and stigmatization, which are also related to the use of tobacco. The social aspects of the PSF program were the most appreciated part of the program by participants. This finding may be useful for future studies.

The present study has produced highly promising results and shows that smoking cessation is possible among HIV-positive people who are motivated to quit. Perhaps future studies should be of a longer duration, both to provide more social support for participants and to assess how long they are able to remain smoke free.

## Resources:

- [CATIE-News: Understanding Tobacco Addiction](#)
- Canadian Cancer Society: [Smoking and tobacco](#)
- Canadian Lung Association: [Smoking & tobacco](#)
- Santé et services sociaux Québec: [Tobacco and your health](#)
- CATIE: [Up in Smoke - The ifs, ands or buts of butting out](#)
- CATIE Factsheet: [HIV and Cardiovascular disease](#)

—Sean R. Hosein

## REFERENCES:

1. Gong J, Hutter CM, Baron JA, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. *Cancer Epidemiology, Biomarkers & Prevention* . 2012; *in press* .
2. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. *HIV Medicine* . 2012; *in press* .
3. Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. *American Journal of Health Behavior* . 2012 Jan;36(1):75-85.
4. Moadel AB, Bernstein SL, Mermelstein RJ, et al. A Randomized Controlled Trial of a Tailored Group Smoking Cessation Intervention for HIV-Infected Smokers. *Journal of Acquired Immune Deficiency Syndromes*. 2012 Oct 1;61(2):208-215.
5. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. *American Journal of Public Health*. 2010 Oct;100(10):1896-903.
6. Lauder W, Mummery K, Jones M, et al. A comparison of health behaviours in lonely and non-lonely populations. *Psychology, Health, and Medicine* . 2006 May;11(2):233-45.

## Produced By:



Canada's source for  
HIV and hepatitis C  
information

555 Richmond Street West, Suite 505, Box 1104  
Toronto, Ontario M5V 3B1 Canada  
Phone: 416.203.7122  
Toll-free: 1.800.263.1638  
Fax: 416.203.8284  
www.catie.ca  
Charitable registration number: 13225 8740 RR

## Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

## Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.*

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at:

<https://www.catie.ca/en/catieneews/2012-10-19/smoking-cessation-innovative-group-therapy-centered-support-found-double-quit-r>